Unravelling driver genes as potential therapeutic targets in ovarian cancer via integrated bioinformatics approach

J Ovarian Res. 2024 Apr 23;17(1):86. doi: 10.1186/s13048-024-01402-7.


Target-driven cancer therapy is a notable advancement in precision oncology that has been accompanied by substantial medical accomplishments. Ovarian cancer is a highly frequent neoplasm in women and exhibits significant genomic and clinical heterogeneity. In a previous publication, we presented an extensive bioinformatics study aimed at identifying specific biomarkers associated with ovarian cancer. The findings of the network analysis indicate the presence of a cluster of nine dysregulated hub genes that exhibited significance in the underlying biological processes and contributed to the initiation of ovarian cancer. Here in this research article, we are proceeding our previous research by taking all hub genes into consideration for further analysis. GEPIA2 was used to identify patterns in the expression of critical genes. The KM plotter analysis indicated that the out of all genes 5 genes are statistically significant. The cBioPortal platform was further used to investigate the frequency of genetic mutations across the board and how they affected the survival of the patients. Maximum mutation was reported by ELAVL2. In order to discover viable therapeutic candidates after competitive inhibition of ELAVL2 with small molecular drug complex, high throughput screening and docking studies were used. Five compounds were identified. Overall, our results suggest that the ELAV-like protein 2-ZINC03830554 complex was relatively stable during the molecular dynamic simulation. The five compounds that have been found can also be further examined as potential therapeutic possibilities. The combined findings suggest that ELAVL2, together with their genetic changes, can be investigated in therapeutic interventions for precision oncology, leveraging early diagnostics and target-driven therapy.

Keywords: Docking; Hub genes; MD simulation therapeutic targets; Ovarian cancer; Prognostic relevance; RNA-binding proteins.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Computational Biology* / methods
  • ELAV-Like Protein 2 / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Regulatory Networks
  • Humans
  • Molecular Docking Simulation
  • Molecular Targeted Therapy
  • Mutation
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics


  • Biomarkers, Tumor
  • ELAV-Like Protein 2

Grants and funding